Hypothermia remains effective in cardiac arrest patients with preexisting cardiomyopathy
November 15, 2011
Cardiomyopathy is common among cardiac arrest survivors. The survival and neuroprotective benefits of therapeutic hypothermia is similar in patients with preexisting cardiomyopathy, compared with those patients without cardiomyopathy, according to a scientific poster being presented Nov. 14 at the at the American Heart Association (AHA) scientific sessions in Orlando, Fla. Therefore, the researchers recommended the use of therapeutic hypothermia in patients with the preexisting condition.
"While it is well established that therapeutic hypothermia is neuroprotective and increases survival in resuscitated cardiac arrest patients without cardiomyopathy, we sought to determine whether catastrophic outcomes in cardiac arrest patients with preexisting cardiomyopathy are avoidable," said Michael R. Mooney, MD, a cardiologist at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis and physician researcher with Minneapolis Heart Institute Foundation.
From February 2006 to July 2010, Mooney and his colleagues enrolled 192 consecutive cardiac arrest patients who remained unresponsive following return of spontaneous circulation in a therapeutic hypothermia protocol, regardless of initial rhythm, hemodynamic status or prior medical history. They hypothesized that there would be a high prevalence of preexisting cardiomyopathy in this patient population, and therapeutic hypothermia would confer similar neurologic and survival benefit compared to non-cardiomyopathy patients.
Of the 192 patients, 43.8 percent had preexisting cardiomyopathy, of which ischemic was the most common type (41.7 percent). Patients with preexisting cardiomyopathy were older (65.7 years vs. 61.7 years) and more likely to be male (83.3 vs. 63.9 percent).
The majority presented in ventricular fibrillation/ventricular tachycardia (75 percent and 70.4 percent) in both the cardiomyopathy and non-cardiomyopathy groups. There was a higher prevalence of concurrent STEMI in the cardiomyopathy group (27 vs. 18.5 percent), which was not statistically significantly. Cardiogenic shock was more prevalent in the cardiomyopathy group (54.8 vs. 28.7 percent).
While the cardiomyopathy groups were slightly higher, the survival between the two groups (52.4 vs. 51.9 percent) and survival with favorable neurologic outcome, defined by Cerebral Performance Category 1 or 2, (46.4 vs. 49.1 percent), were similar. They found that survival with favorable neurologic outcome in cardiomyopathy patients with cardiogenic shock was 34.8 percent, compared with 45.2 percent in non-cardiomyopathy cardiogenic shock patients.
"The incidence of preexisting heart dysfunction in this observational study is alarming. In general, we need to employ a more careful surveillance and improve our adherence to the clinical guidelines, as less than 50 percent of patients who currently qualify for automatic implantable cardioverter-defibrillators actually receive them," Mooney said. "A great deal more research is warranted in assessing this patient population."
Minneapolis Heart Institute Foundation
Related Cardiomyopathy Current Events and Cardiomyopathy News ArticlesIs endurance training bad for you?
In 2012, Belgium scientists published a study that concluded that repeated bouts of intensive endurance exercise at the elite level may result in the pathological enlargement of the right ventricle, which, according to the article, is associated with potential health hazards including sudden cardia death.New study uncovers mechanisms underlying how diabetes damages the heart
Cardiac complications are the number one cause of death among diabetics. Now a team of scientists has uncovered a molecular mechanism involved in a common form of heart damage found in people with diabetes.Heart failure patients have improved outcomes following investigational stem cell treatment
An investigational stem cell therapy derived from patients' own blood marrow significantly improved outcomes in patients with severe heart failure, according to a study from the Cedars-Sinai Heart Institute.Stem cell therapy improves outcomes in severe heart failure
A new stem cell therapy significantly improved long-term health outcomes in patients with severe and end-stage heart failure in a study presented at the American College of Cardiology's 65th Annual Scientific Session.New device for heart failure patients fails to improve primary outcomes
A new implantable medical device intended to help patients with heart failure by stimulating the vagus nerve did not significantly reduce rates of heart failure-related hospitalization or death from any cause in a study presented at the American College of Cardiology's 65th Annual Scientific Session.Pioneering discovery leads to potential preventive treatment for sudden cardiac death
More than 15 years ago, David Warshaw, Ph.D., and coworkers discovered the precise malfunction of a specific protein in the heart that leads to hypertrophic cardiomyopathy, a common culprit in cases of sudden death in young athletes.Gene-editing technique successfully stops progression of Duchenne muscular dystrophy
Using a new gene-editing technique, a team of scientists from UT Southwestern Medical Center stopped progression of Duchenne muscular dystrophy (DMD) in young mice.TGen and Barrow identify genes linked to stress-triggered heart disease
Researchers at the Translational Genomics Research Institute (TGen) and Barrow Neurological Institute have for the first time identified genetic risk factors that are linked to stress-induced cardiomyopathy (SIC), a rare type of heart disease.Manipulating cell signaling for better muscle function in muscular dystrophy
Every heart beat and step in our daily lives is dependent on the integrity of muscles and the proteins that keep them strong and free of injury as they contract and relax. Targeted chemotherapy shows early signs of slowing tumor growth with less toxicity
Surviving neuroblastoma as a child can come with just as many challenges as the cancer itself, mainly because of the toxic effects of chemotherapy.
More Cardiomyopathy Current Events and Cardiomyopathy News Articles
Cardiomyopathies: Classification, Evaluation and Management|
by Bernard Tyler (Editor)
Cardiomyopathies are defined as myocardial disease which leads to abnormal heart muscle. This book presents a complete, up to date examination of the current information available regarding cardiomyopathies. It presents the complete cardiovascular system as a functional unit, and the various contributors to this book analyze pathophysiological mechanisms from diverse viewpoints, by giving a classification, evaluation and management of cardiomyopathies. This book presents a broad overview of cardiomyopathies which will be of interest to researchers in this field.
A Simple Guide To Cardiomyopathy, Diagnosis, Treatment And Related Conditions (A Simple Guide to Medical Conditions)|
My mother had cardiomyopathy; so did her mother and brother both of whom died from heart failure.
My brother also had aortic regurgitation which had been treated but still has heart failure.
When I was 12 and down with mumps, I remembered my mother resting at home supposedly suffering from a mild heart attack after a strenuous period of school work.
The doctors all thought that she had ischemic heart disease.
When I was a medical student, I decided to have an ECG done on myself and found that I had mild right bundle branch block which was thought to be congenital and not serious at that time.
Medical students always have the tendency to think that they have the same disease that they read...
Cardiomyopathy...Keeping you on Track|
Non fiction. This book was written for the 20th anniversary of the Association known as Cardiomyopathy Australia and celebrated with the biennial seminar at the culmination of Cardiomyopathy Week 2014 that runs from September 7 to Saturday September 13.
This book tells the story of the beginnings of the Association and its founder, the late Robyn Bell. Details of what cardiomyopathy is, what types of this disease are known, members stories and helpful advice for patients and carers, are all explained in this book.
The Introduction to the book was written by the Cardiomyopathy Australia President, Alistair Kerr and the Foreword written by eminent Australian cardiologist Dr Mark Ryan.
A Guide to Hypertrophic Cardiomyopathy: For Patients, Their Families and Interested Physicians|
by Barry J. Maron (Author), Lisa Salberg (Author)
Written by the authority on hypertrophic cardiomyopathy (HCM) and an HCM patient, and fully endorsed by the Hypertrophic Cardiomyopathy Association (HCMA), the leading advocacy and support organization, the 3rd Edition of this best-selling guide offers unparalleled insight into all aspects of living with and treating HCM. Accessible and practical, A Guide to Hypertrophic Cardiomyopathy For Patients, Their Families and Interested Physicians 3rd Edition: Answers the most pressing questions posed by patients, their families, and non-specialists
health professionals involved in their care Covers everything from what is HCM and initial diagnosis of this increasingly prevalent
condition to the latest treatment options Reflects the first-ever HCM guidelines published by the American...
Cardiomyopathy - A Reference Guide (BONUS DOWNLOADS) (The Hill Resource and Reference Guide Book 92)|
by Capitol Hill Press
18 Health and Disease Professional Textbooks (over 5,300 pages) For Your E-Reader
* BONUS Encyclopedia of Disease (14 volumes, 4,625 pages)
* BONUS Dictionary of Clinical Research Terms (268 pages)
* BONUS Dictionary of Psychiatry Terminology (167 pages)
* BONUS The Complete Guide to Alternative and Complementary Medicine (135 pages)
* BONUS The Truth About Herbal Cures (106 pages)
Note: For best results and the most comprehensive reading and research experience, please use book in conjunction with the bonus downloads.
The Hill Resource and Reference Guide series is a comprehensive and authoritative source of quality health research sources for both the layperson and medical health...
Understanding Cardiomyopathy in plain English|
SO YOU HAVE BEEN TOLD YOU HAVE CARDIOMYOPATHY NOW WHAT? YOU ASK.
I WILL EXPLAIN IT IN PLAIN ENGLISH WHAT IT MEANS TO YOU AND HOW IT AFFECTS YOU.
What's Left of Me|
by Amanda Maxlyn, LLC
An International and Amazon top 50 bestselling novel.
"I absolutely fell in love with What’s Left of Me by Amanda Maxlyn. With an uncanny ability to weave an intensely emotional story into a sexy romance, Maxlyn is a debut author you do not want to miss." – AL Jackson, NYT and USA Today Best Selling Author
Life works in mysterious ways...
Four years ago I became known as the girl with cancer.
I refuse to cry. And I refuse to give in.
A relationship with a man is the last thing I’m looking for right now, but one night with Parker changes everything. He is persistent, and he knows what he wants.
He doesn’t treat me like I’m fragile. But he doesn’t know, and I’m not ready to tell him.
Don't Take Heart Transplant For an Answer - Cardiomyopathy Treatment Action Plan|
Studies show that of all the organs in the human body, the heart is by far the most receptive to nutritional treatment.
After watching my son go to the cardiologist repeatedly and never seeing considerable improvement for his dilated cardiomyopathy, they were suggesting that a heart transplant would ultimately be the solution. I wasn’t about to simply stand by without researching as much as I could to help him. He had an ejection fraction of just 15%. A normal reading for this is 55% to 65%.
"Don't Take Heart Transplant for an Answer - Cardiomyopathy Treatment Action Plan" provides in-depth details about a congestive heart failure action plan that is relevant to the various types of cardiomyopathy, such as dilated, hypertrophic and restrictive cardiomyopathy.
Dilated Cardiomyopathy - ECAB|
by Elsevier India
Dilated cardiomyopathy (DCM) is traditionally referred to as idiopathic dilated cardiomyopathy (IDC), which includes genetic forms of DCM. The patients present with a wide range of symptoms like dyspnea, orthopnea, paroxysmal nocturnal dyspnea, arrhythmias or complications associated with DCM. The diagnosis is based on exclusion of the various identifiable causes of systolic left ventricular dysfunction, such as ischemic cardiomyopathy, hypertensive cardiomyopathy, alcoholic cardiomyopathy, myocarditis secondary to viral or other causes, peripartum cardiomyopathy and cardiomyopathies secondary to amyloidosis, hemochromatosis, sarcoidosis, and due to drug toxicity. The sophisticated and expensive diagnostic tests might not be feasible for a typical Indian patient. This prompts us to...
Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald|
by Srihari Naidu (Editor)
This book provides a comprehensive clinical review of Hypertrophic Cardiomyopathy (HCM), the most common genetic disorder of the heart characterized by dysfunctional contractility at the sarcomere level, resulting in the development of abnormal and occasionally focal hypertrophy on a macroscopic level. Editor, Srihari S. Naidu, has brought together a world renowned group of experts to review various different topics but, with a practical focus that will enable readers to establish the evidence-based best practice in any potential scenario. Treatment modalities including medications, pacemakers and defibrillators, and invasive septal reduction therapy (both surgical myectomy and alcohol septal ablation) will be discussed. Chapters on genetics, family screening, lifestyle concerns, and...